Hemosuccus Pancreaticus Due to the Rupture of a Pseudoaneurysm That Developed in an Intraductal Papillary Mucinous Neoplasm

Taisuke Obata, Kazuyuki Matsumoto, Hironari Kato, Tatsuhiro Yamazaki, Yuki Fujii, Takeshi Tomoda, Shigeru Horiguchi and Hiroyuki Okada

Abstract:
A 76-year-old woman with branch duct intraductal papillary mucinous neoplasm (IPMN) was admitted with epigastric pain and vomiting. She had received warfarin due to a history of deep vein thrombosis. A blood test showed decreased serum hemoglobin and elevated serum amylase. Contrast-enhanced computed tomography revealed acute pancreatitis and formation of a pseudoaneurysm in the IPMN. We suspected rupture of a pseudoaneurysm and performed trans-catheter angiography. Angiography showed extravasation from the posterior superior pancreaticoduodenal artery, and coil embolization was performed. It is important to be alert for the formation of pseudoaneurysm in patients with cystic neoplasms.

Key words: hemosuccus pancreaticus, IPMN, pseudoaneurysm, anticoagulation drug

Introduction
Hemosuccus pancreaticus (HP) is a rare disease involving bleeding from the papilla of Vater via the pancreatic duct (1). HP is associated with a high mortality rate of 25-40% (2-4); hemorrhagic shock is the most common cause of death (5). HP is mostly caused by acute or chronic pancreatitis, and aneurysms often occur in association with HP. There are a few reports of patients with pancreatic cystic neoplasms that developed HP; surgical treatment was usually performed for the control of HP in those cases.

We herein report a case of HP caused by intraductal papillary mucinous neoplasm (IPMN) with a pseudoaneurysm during anticoagulation drug treatment that was successfully treated with interventional radiography (IVR).

Case Report
The patient was a 76-year-old woman with branch duct IPMN (BD-IPMN) of the pancreatic head that had been followed up regularly with imaging studies twice a year for 8 years (Fig. 1). We also performed endoscopic ultrasonography, but no findings suggestive of malignancy in the IPMN were noted (Fig. 2). She had been treated with warfarin due to a history of deep vein thrombosis. The warfarin dose was 2.25 mg/day and had been optimally controlled for 13 years after she received bilateral total knee arthroplasty. She had no notable family history or drinking habit.

Within seven days before the next follow-up, she was urgently admitted to our hospital with epigastric pain and vomiting. Her heart rate was 85/minute, systolic blood pressure was 145 mmHg, diastolic blood pressure was 85 mmHg, and body temperature was 37.0°C. Her abdomen was soft and flat. She had epigastric pain as well as pain in her back, but no tenderness or rebound was observed. A blood test showed a decreased serum hemoglobin level (12.2 to 10.9 g/dL), elevated serum amylase, and a slightly increased international ratio due to the administration of warfarin (Table 1). Contrast-enhanced (CE) computed tomography (CT) revealed acute pancreatitis and the formation of a pseudoaneurysm in the IPMN (Fig. 3). Based on the sudden onset of her symptoms and the blood test results, we suspected that rupture of a pseudoaneurysm. We performed
trans-catheter angiography, which revealed extravasation from the posterior superior pancreaticoduodenal artery (PSPA) and performed coil embolization of the PSPA (Fig. 4). Melena was observed three times on the day after the procedure; however, this resolved naturally without the progression of anemia. Based on these findings, we diagnosed the patient with HP caused by the sudden rupture of a pseudoaneurysm.

Her clinical course is shown in Fig. 5. She was discharged on the eighth day after the coil embolization. Follow-up CT revealed that the pseudoaneurysm had been completely treated and that the findings of acute pancreatitis were improved (Fig. 6). Although we recommended surgery (pancreaticoduodenectomy) for the prevention of recurrence of pancreatitis, she refused surgical treatment. Thus, she has been carefully followed up with imaging studies. There have

**Figure 1.** Contrast-enhanced computed tomography showed multiple cystic lesions suspected of being IPMN in the pancreas (arrows). IPMN: intraductal papillary mucinous neoplasm

**Figure 2.** Endoscopic ultrasonographic findings. Left: B mode, Right: contrast mode. Findings of wall thickening in the IPMN were noted, but there were no nodules on contrast EUS mode. IPMN: intraductal papillary mucinous neoplasm, EUS: endoscopic ultrasonography

| Laboratory Data on the Admission. |
|-----------------------------------|
| Hematologic test                  |
| White blood cells                | AST    | 27 U/L |
| 11,820 /μL                       | ALT    | 17 U/L |
| Red blood cells                  | ALT    | 17 U/L |
| 5.57×10⁹ /μL                     | ALP    | 168 U/L|
| Hemoglobin                       | γ-GTP  | 13 U/L |
| 10.9 g/dL                        | LDH    | 249 U/L|
| Platelet count                   | LDH    | 249 U/L|
| 23.9×10⁴ /μL                     |        |        |
| Coagulation                      | Amylase| 3,568 U/L|
| PT                               |        |        |
| 33 %                             |        |
| PT-INR                           | Creatinine| 1.06 mg/dL|
| 1.82                             | Sodium | 141 mmol/L|
| Fibrinogen                       | Potassium| 4.4 mmol/L|
| 291 mg/dL                       | Chloride| 103 mmol/L|
| Chemistry                        | CRP    | 0.68 mg/dL|
| Total protein                    | glucose| 161 mg/dL|
| 6.1 g/dL                         |        |
| Albumin                          | CRP    | 0.68 mg/dL|
| 4.1 g/dL                         | glucose| 161 mg/dL|
| Total bilirubin                  | HbA1c  | 6.2 %   |
| 0.67 mg/dL                      |        |
| Direct bilirubin                 |        |
| 0.15 mg/dL                      |        |

PT: prothrombin time, PT-INR: prothrombin time-international normalized ratio, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, γ-GTP: γ-glutamyl transpeptidase, LDH: lactate dehydrogenase, BUN: blood urea nitrogen, CRP: C-reaction protein, HbA1c: hemoglobin A1c
Discussion

We herein report a rare case of HP caused by IPMN with a pseudoaneurysm during anticoagulation drug treatment. HP due to a pseudoaneurysm caused by a cystic neoplasm of the pancreas is rare. We successfully controlled the bleeding from a pseudoaneurysm using IVR.

According to a review of cases of HP, the main causes of HP are arterial aneurysm, inflammatory changes in the pancreas (acute and/or chronic), and pancreatic tumors (6, 7). Ru Nan et al. summarized 114 HP cases (6), and the causes of HP were pancreatitis in 95 cases (82.6%), pancreatic tumor in 18 cases (16.5%), and congenital pancreatic malformation in 1 case (0.9%). The breakdowns of pancreatic tumors were cystadenoma in 8 cases (7.0%), IPMN in 5 cases (4.3%), endocrine tumors in 2 cases (1.7%), adenocarcinoma in 1 case (0.9%), and carcinoma in situ in 1 case (0.9%). Many studies have reported that the direct source of bleeding was a ruptured aneurysm; the most common site of causative aneurysms is the splenic artery (8-10). Aneurysms of the pancreatic and pancreaticoduodenal arteries are rare, accounting for only 2% of all splanchnic artery aneurysms (9), and peripancreatic aneurysms are among the most life-threatening of all splanchnic artery aneurysms (10).

In the diagnosis of HP, esophagogastroduodenoscopy (EGD) is a useful examination for confirming hemorrhaging from the main papilla. However, according to a report by Vimalraj et al. summarizing 31 HP cases, bleeding from the papilla was confirmed in about half of their 16 cases (51%). CE-CT (90%; 28/31) and angiography (88%; 23/26) depicted positive findings for HP (11). Thus, in some cases, bleeding from the papilla could not be detected, and these cases were diagnosed with HP based on other radiographic findings and the clinical course [of note, some cases were diagnosed by surgery (12)]. In the present case, HP was suspected because 1) anemia had progressed according to blood test findings, 2) there was extravasation from a pseudoaneurysm in the IPMN on CE-CT and IVR, 3) there was evidence of acute pancreatitis, and 4) melena appeared in the subsequent clinical course. We therefore diagnosed the pa-
The main treatments of HP are IVR and surgery. Once the patient is hemodynamically stable, IVR procedures are effective as an initial treatment in 67-100% of cases (13). If the source of bleeding is found on angiography, IVR procedures are the first choice for initial management, with immediate good results in 79-100% of cases and an overall success rate of 67% (14, 15). For patients with hemodynamic instability, emergency operations are inevitable. Distal pancreatectomy is a surgical alternative to IVR procedures for a bleeding pancreatic pseudoaneurysm in the body or tail of the pancreas. However, when the pseudoaneurysm is located in the head of the pancreas, surgical resection is associated with increased mortality and morbidity, and IVR procedures have been proposed as the recommended treatment modality in such cases. In the present case, the patient’s vital signs were stable, and the pseudoaneurysm was found in the IPMN at the head of the pancreas. The source of bleeding was found on angiography, and coil embolization was successfully performed. As a result, we were able to control the HP and avoid emergency surgery.

There have been eight reported cases of HP due to pancreatic cystic neoplasms in the relevant literature (16-23) (Table 2). Including our case, 5 cases (56%) were IPMN, and 2 cases each (22%) were mucinous cystic neoplasms and serous cystic neoplasms. The median age was 67 years old, and 4 of the patients (44%) were men. The median tumor size was 31 mm, and most of the tumors were ≥20 mm in diameter. Most of the tumors were located at the pancreatic body or tail. The causes of HP included bleeding from the tumor in 5 cases (56%) and rupture of an arterial pseudoaneurysm in 4 cases (44%). Two cases were treated with an antithrombotic drug. Most cases were treated with surgery, and two cases (including our case) were treated with an IVR procedure. The rupture of a splenic artery aneurysm was mostly seen as the cause of HP, and this is the first reported case with a ruptured PSPA pseudoaneurysm.

IPMN may reportedly cause HP due to pancreatic cystic neoplasms in association with concomitant pancreatitis or hemorrhaging associated with tumor necrosis (20). In patients with IPMN, the blood vessel walls are exposed to viscous pancreatic juice. Such long-term exposure can cause the rupture of the elastic fibers in the vessel wall, forming an extravascular circulation space with the fibrous cap and thus creating a pseudoaneurysm (24). In this case, warfarin treatment with HP based on these radiographic findings and the clinical course.

Figure 5. The clinical course from admission to discharge. IVR: interventional radiology, AMY: amylase, Hb: hemoglobin, BUN: blood urea nitrogen

Figure 6. Follow-up CT revealed that the pseudoaneurysm had been completely treated, and the findings of acute pancreatitis had improved.
Table 2. Hemosuccus Pancreaticus with Pancreatic Cyst Neoplasms.

| Reference no. | Age | Sex | Neoplasms | Antithrombotic therapy | Cause of HP | Treatment |
|---------------|-----|-----|------------|------------------------|-------------|-----------|
| 16            | 57  | F   | SCN tail   | n.d.                   | rupture of SA aneurysm | surgery    |
| 17            | 71  | F   | MCN tail   | n.d.                   | tumor bleeding | surgery   |
| 18            | 58  | M   | IPMN tail  | n.d.                   | rupture of SA aneurysm | surgery   |
| 19            | 35  | F   | SCN head/tail | n.d.               | tumor bleeding | surgery   |
| 20            | 78  | M   | IPMN tail  | antiplatelet (ticlopidine) | tumor bleeding | surgery   |
| 21            | 62  | F   | MCN tail   | n.d.                   | tumor bleeding | surgery   |
| 22            | 67  | M   | IPMN body  | n.d.                   | rupture of SA aneurysm | IVR       |
| 23            | 79  | M   | IPMN body  | n.d.                   | tumor bleeding | surgery   |
| our case      | 76  | F   | IPMN head  | anticoagulation (warfarin) | rupture of PSPA aneurysm | IVR       |

HP: hemosuccus pancreaticus, SA: splenic artery, PSPA: posterior superior pancreaticoduodenal artery, SCN: serous cystic neoplasm, MCN: mucinous cystic neoplasm, IPMN: intraductal papillary mucinous neoplasm, IVR: interventional radiology, n.d.: no data, F: female, M: male

was controlled in the therapeutic range, and its involvement in the bleeding from the cyst is unclear. However, a case of HP in which a cystic neoplasm developed under antithrombotic therapy was previously reported (20), so further investigations concerning the relationship between antithrombotic therapy and HP should be conducted in the future.

Conclusions

We encountered a case of HP due to rupture of a pseudoaneurysm in a patient with IPMN. It is important to be alert for the formation of pseudoaneurysms when we follow patients with cystic neoplasms.

The authors state that they have no Conflict of Interest (COI).

References

1. Sandblom P. Gastrointestinal hemorrhage through the pancreatic duct. Ann Surg 171: 61-66, 1970.
2. Stabile BE, Wilson SE, Debas HT. Reduced mortality from bleeding pseudocysts and pseudoaneurysm caused by pancreatitis. Arch Surg 118: 45-51, 1983.
3. Fren CF. Pancreatic pseudocyst-operating strategy. Ann Surg 188: 652-662, 1978.
4. Gadacz TR, Trunkey D, Kieffer RF Jr. Visceral vessel erosion associated with pancreatitis. Case reports and a review of the literature. Arch Surg 113: 1438-1440, 1978.
5. Greenstein A, DeMaio EF, Nabel SE. Acute hemorrhage associated with pancreatic pseudocysts. Surgery 69: 56-62, 1971.
6. Ru N, Zou WB, Qian YJ, et al. A systematic review of the etiology, diagnosis, and treatment of hemosuccus pancreaticus. Pancreas 48: e47-e49, 2019.
7. Peng Yu, Jianping Gong. Hemosuccus pancreaticus: a mini-review. Ann Med Surg (Lond) 28: 45-48, 2018.
8. Matsumoto I, Ueda T, Ajiki T, et al. A case of successful treatment with transcatheter arterial embolization for a ruptured aneurysm of the gastroduodenal artery presenting with a hemosuccus pancreaticus. Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 103: 1397-1402, 2006 (in Japanese, Abstract in English).
9. Stanley JC, Wakefield TW, Graham LM, et al. Clinical importance and management of splanchic artery aneurysms. J Vasc Surg 3: 836-840, 1986.
10. Stanley JC, Fren CF, Miller TA, Lindemauer SM, Child G 3rd. Major arterial hemorrhage: a complication of pancreatic pseudo cysts and chronic pancreatitis. Arch Surg 111: 435-440, 1976.
11. Vimalraj V, Kannan DG, Sukumar R, et al. Hemosuccus pancreaticus: diagnostic and therapeutic challenges. HPB (Oxford) 11: 345-350, 2009.
12. Sakorafas GH, Sarr MG, Farley DR, et al. Hemosuccus pancreaticus complicating chronic pancreatitis: an obscure cause of upper gastrointestinal bleeding. Langenbecks Arch Surg 385: 124-128, 2000.
13. Gambiez LP, Ernst OJ, Merlier OA, Porte HL, Chambon JP, Quandalle PA. Arterial embolization for bleeding pseudocysts complicating chronic pancreatitis. Arch Surg 132: 1016-1021, 1997.
14. Han B, Song ZF, Sun B. Hemosuccus pancreaticus: a rare cause of gastrointestinal bleeding. Hepatobiliary pancreat Dis Int 11: 479-488, 2012.
15. Zyromski NJ, Vieira C, Stecker M, et al. Improved outcomes in postoperative and pancreatitis-related visceral pseudoaneurysms. J Gastrointest Surg 11: 50-55, 2007.
16. Pinarbas I, Poturougu S, Yanar H, et al. A rare case of hemosuccus pancreaticus: Primary splenic artery aneurysm ruptured into pancreatic serous cystadenoma. Turk J Gastroenterol 19: 57-63, 2008.
17. Shizuki M, Hori Y, Fujino Y, et al. Mucinous cystic neoplasm of the pancreas presenting with hemosuccus pancreaticus. Surg Today 40: 470-473, 2010.
18. Igari K, Watanabe Y, Aihara A, et al. Two cases of hemosuccus pancreaticus. Nihon Shokakibyo Geka Gakkai Zasshi (Jpn J Gastroenterol Surg) 43: 1246-1251, 2010 (in Japanese, Abstract in English).
19. Kanno A, Satoh K, Hamada S, et al. Serous cystic neoplasm presenting as hemosuccus pancreaticus. Surg Today 50: 1293-1298, 2011.
20. Inoue H, Katsurahara M, Takei Y. Intraductal papillary mucinous neoplasm presenting as hemosuccus pancreaticus. Clin Gastroenterol Hepatol 13: 57-58, 2015.
21. Matsumoto Y, Miyamoto H, Fukuya A, et al. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas. Clin J Gastroenterol 10: 185-190, 2017.
22. Nakamura T, Ikeda A, Itakaya Y, et al. A case of relapsed hemosuccus pancreaticus successfully treated with interventional radiology. Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 115: 825-832, 2018 (in Japanese, Abstract in English).
23. Sugiuira R, Kinoshit K, Naruse H, et al. Hepatobiliary and pancreatic: hemosuccus pancreaticus due to an intraductal papillary mucinous neoplasm: a rare cause of obscure gastrointestinal bleeding.
Nagamatsu H, Takahashi K, Ueo T, et al. A case of splenic artery aneurysm simulating a pancreas tumor. Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 108: 1420-1427, 2011 (in Japanese, Abstract in English).